(NASDAQ: RVMD) Revolution Medicines's forecast annual revenue growth rate of 142.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.01%.
Revolution Medicines's revenue in 2026 is $197,559,000.On average, 27 Wall Street analysts forecast RVMD's revenue for 2026 to be $56,837,296,638, with the lowest RVMD revenue forecast at $10,911,947,695, and the highest RVMD revenue forecast at $159,145,728,340. On average, 26 Wall Street analysts forecast RVMD's revenue for 2027 to be $304,107,006,138, with the lowest RVMD revenue forecast at $63,589,942,962, and the highest RVMD revenue forecast at $766,323,700,389.
In 2028, RVMD is forecast to generate $622,273,013,271 in revenue, with the lowest revenue forecast at $275,556,419,502 and the highest revenue forecast at $1,015,925,041,131.